Introduction

Pleurodesis aims to obliterate the pleural space by producing extensive adhesion of the visceral and parietal pleura, in order to control relapse of either pleural effusions (mostly malignant) or pneumothorax. A tight and complete apposition between the two pleural layers is a necessary condition to obtain a successful pleurodesis, but – besides this mechanical aspect – there are many biological mechanisms that appear to be common to most of the sclerosing agents currently used. Following intrapleural application of the sclerosing agent, diffuse inflammation, pleural coagulation-fibrinolysis imbalance (favoring the formation of fibrin adhesions), recruitment and subsequent proliferation of fibroblasts, and collagen production are findings in the pleural space. The pleural mesothelial lining is the primary target for the sclerosant and plays a pivotal role in the whole pleurodesis process, including the release of several mediators like interleukin-8, transforming growth factor-β and basic fibroblast growth factor. When the tumor burden is high, normal mesothelial cells are scarce, and consequently the response to the sclerosing agent is decreased, leading to failure of pleurodesis. Also, the type of tumor in the pleural cavity may also affect the outcome of pleurodesis (diffuse malignant mesothelioma and metastatic lung carcinomas have a poorer response). There is general agreement that talc obtains the best results, and there are also preliminary experimental studies suggesting that it can induce apoptosis in tumor cells and inhibit angiogenesis, thus contributing to a better control of the malignant pleural effusion. There is concern about complications (possibly associated with talc but other agents as well) related to systemic inflammation and possible activation of the coagulation cascade. In order to prevent extrapleural talc dissemination, large-particle talc is recommended. Although it could – to some degree – interfere with the mechanisms leading to pleurodesis and a carefully balanced clinical decision has therefore to be made, prophylactic treatment with subcutaneous heparin is recommended during hospitalization (immediately before and after the pleurodesis procedure).

pneumothorax [1, 2]. However, it can also be required in some benign effusions.

Most of the patients undergoing a pleurodesis procedure have symptomatic MPE. When this condition is diagnosed, palliative therapy should be considered with special evaluation of the patient’s symptoms, general health, functional status and expected survival.

The main indication for treatment in such cases is to alleviate dyspnea, which is dependent on both the volume of the effusion and the underlying condition of the lungs and pleura. Therapeutic thoracentesis should be performed in virtually all dyspneic patients with MPE to determine its effect on breathlessness, and rate and degree of recurrence. This is especially important in patients presenting a massive pleural effusion and a contralateral mediastinal shift. Those particular cases are the obvious candidates for a pleurodesis procedure.

Management of the patients could vary according to their clinical condition. Thus, rapid recurrence of the effusion indicates the need for immediate treatment, and stability and absence of symptoms requires a closer follow-up.

According to the ATS/ERS consensus statement on the Management of Malignant Pleural Effusions [3], the following definitions were proposed for efficacious treatment.

**Successful Pleurodesis**

**Complete Success.** Long-term relief of symptoms related to the effusion, with absence of fluid reaccumulation on chest radiographs until death.

**Partial Success.** Diminution of dyspnea related to the effusion, with only partial reaccumulation of fluid (radiographic evidence of <50% of the initial fluid), with no further therapeutic thoracentesis required during the follow-up.

**Failed Pleurodesis.** Lack of success as it is defined above.

Comparative studies of different pleurodesis techniques should evaluate outcome using time-to-event analyses and censor patients who are lost to follow-up. Data should be reported with and without inclusion of patients who die within 1 month of pleurodesis.

**Mechanisms Involved in Pleurodesis**

In order for pleurodesis to be successful, several conditions have to be taken into account.

---

Rodriguez-Panadero/Montes-Worboys

*Respiration 2012;83:91–98*
mokines in the pleural space [5]. After the recruitment of neutrophils, they secrete a variety of cytokines responsible for the perpetuation of the inflammatory pathway. The inflammatory response to the sclerosant can be significantly inhibited by corticosteroids [6], and according to our knowledge – simultaneous steroid treatment is associated with an increased rate of pleurodesis failure in clinical practice.

**Coagulation Cascade and Decrease in the Pleural Fibrinolytic Activity**

A second critical response to a sclerosing agent is the initiation of the coagulation cascade and the decrease in the pleural fibrinolytic activity. This is necessary for the early formation of fibrin links between the visceral and parietal pleura, which further provoke the symphysis of the two pleural layers [7]. Agrenius et al. [8, 9] demonstrated an increase in pleural coagulation and a decrease in fibrinolytic activity after the instillation of a sclerosing agent. It is assumed that the formation of a fibrin mesh is necessary for the recruitment and subsequent proliferation of fibroblasts in the pleural space. In this regard, we hypothesized a few years ago that either an impaired fibrin formation or an increase in endopleural fibrinolysis would lead to pleurodesis failure. Our group demonstrated that failure of talc pleurodesis is associated with an increased pleural fibrinolysis [10].

The formation of a fine latticework of fibrin (the end product of the coagulation cascade) between the visceral and parietal pleura initiates the third step of the inflammatory cascade. This process leads to the proliferation of fibroblasts, which form strong adhesive links between the visceral and parietal pleural surfaces, obliterating the pleural space [11]. At least in animal experiments, the initial fibroblast invasion of the fibrinous links between visceral and parietal pleura leads to the organization of well-vascularized and innervated connective tissue that resembles that of the undamaged pleura. Therefore, it appears that pleurodesis is not just a scar produced as a consequence of the repair process, but a structure establishing a functional continuity between both visceral and parietal pleura [12].

Several fibroblast growth factors have been found in the pleural fluid of patients given sclerosing agents. These include platelet-derived growth factor, basic fibroblast growth factor (bFGF) and transforming growth factor-β (TGF-β). Patients with successful pleurodesis presented markedly increased levels of bFGF in the pleural fluid, and those with unsuccessful pleurodesis had significantly lower amounts of bFGF [13]. There appears to be a significant inverse correlation between the release of bFGF in the pleural fluid of patients who have MPE and tumor burden, as evaluated by objective grading during thoracoscopy. Thus, patients with extensive pleural tumor involvement do not have high levels of bFGF released by mesothelial cells. However, when talc is instilled early in the course of malignant pleural disease (thus pleural mesothelial cells remain extensively exposed to the sclerosing agent), the level of bFGF is much higher and pleurodesis successful. This is in agreement with clinical experience; thus, patients with advanced malignant pleural involvement have a worse outcome of treatment compared to those treated early in the course of their disease. Taken together, this indicates that an exuberant and vigorous response by pleural mesothelial cells is critical for the success of pleurodesis.

Mesothelial cells regulate the pleural coagulation-fibrinolysis balance and the first steps of the pleural fibrosis process [14]. Furthermore, there is a growing body of evidence concerning the association of fibrinolytic activity with tumor aggressiveness in other organs, thus suggesting that the strong fibrinolytic activity detected in our cases of pleurodesis failure arises, at least in part, from the neoplastic cells in the pleural space [15]. The normal pleura has an intrinsic fibrinolytic activity due to the production of both urokinase and tissue plasminogen activators by mesothelial cells, and this fibrinolytic activity is markedly increased in most of the MPE patients. In order to invade the surrounding tissue, tumor cells express huge amounts of plasminogen activators (fig. 1) that can be partially blocked by plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2; fig. 2).

Fibrinolytic activity – expressed by D-dimer levels – shows a decline 24 h after talc poudrage in patients who have successful pleurodesis. Moreover, D-dimer activity is not decreased after talc poudrage in patients with unsuccessful pleurodesis [9]. Commercial kits are already available to perform a rapid neutrophil count and D-dimer determination, and the measurement of those parameters will be a useful tool to monitor the ongoing biologic process after intrapleural talc instillation. Thus, patients developing a good inflammatory response show a typical pattern with rapidly increasing neutrophils and declining D-dimer activity in serial samples of pleural fluid after talc poudrage [16]. If this does not occur, or the response to talc is poor, we attempt to enhance the pleurodesis process by increasing the suction rate and prolonging the time of drainage in order to provoke a better pleural symphysis through mechanical irritation and tight apposition of the visceral and parietal pleura layers.
Role of the Mesothelium in Pleurodesis

It was assumed that severe damage to the mesothelial layer was necessary to achieve a pleural symphysis. This is true when mechanical pleural abrasion or pleurectomy is performed, but there is increasing evidence for the new concept that the pleural mesothelium is the primary initiator of the biological mechanisms leading to pleurodesis [17, 18]. We already know that the production/release of inflammatory and fibrosis markers by mesothelial cells are essential to achieve a good pleural symphysis, provided that mechanical conditions, as explained above, have been accomplished. In order to obtain satisfactory results, the sclerosing agent must reach the maximum surface area of normal mesothelium in the pleural space. Thus, when the mesothelial surface is covered by tumor or fibrin, and this circumstance is associated with low glucose and pH levels, the rate of failure is much higher [19–23]. This also explains why much lower doses of sclerosant are required to induce pleurodesis in pneumothorax (in which the mesothelial surface is almost completely preserved). In our thoracoscopy series, we found a complete successful talc pleurodesis in 79% of the patients with pH ≥7.30, whereas it was successful in only 40% of those with pH <7.20, and in none of the patients with pH <7.15 [17]. A low pleural pH has been associated with trapped lung and poor survival, and there are some clues suggesting that a low pH does not only mean that there is a thick visceral pleura with difficult lung reexpansion [24], but that it would also inhibit some of the biological processes leading to a good pleurodesis by itself.

The cellular mechanisms involved in pleurodesis are not yet fully understood, but it seems that – besides mesothelial cells – inflammatory cells recruited from the bloodstream (neutrophils and mononuclear phagocytes) play an essential role [25]. There is also some evidence supporting the interaction between talc, as sclerosing agent, and its uptake in cells from the pleural space [26]; moreover, the specific surface area of the talc appears to have a marked influence on the outcome of pleurodesis. Thus, talcs with small particles have a higher specific surface area and then provoke more stimulation of mesothelial cells through extensive contact of the particles with the cell membrane. The cellular and biochemical mechanisms may be specific for the agent used for pleurodesis, but it seems that – in most of the cases – there is a common final pathway leading to the activation of the pleural...

Fig. 1. Fibrinolytic activators expressed by tumor tissue in pleural metastatic carcinomas. a Marked expression of urokinase plasminogen activator by tumor cells in pleural metastatic carcinoma of the lung. This patient had a very short survival and failure of pleurodesis. b Expression of tissue plasminogen activator by tumor cells in a patient with metastatic carcinoma of the lung, with short survival and poor outcome of pleurodesis. c Expression of urokinase plasminogen activator by tumor cells inside a lymphatic vessel and by other cells invading the surrounding pleural tissue.

Fig. 2. PAI-2 expression by normal mesothelial cells (arrows) in a patient with metastatic carcinoma of the breast (T). This patient had a long survival (>7 years after talc poudrage) and very good results of pleurodesis.
coagulation cascade, the formation of fibrin networks and the proliferation of fibroblasts.

The recruitment and proliferation of fibroblasts in the pleural space are essential for the pleurodesis process, and there is evidence that both tetracycline and talc stimulate mesothelial cells to produce/release fibroblast growth factor [27, 28]. It has been postulated that using TGF-β for pleurodesis would induce effective – and faster than talc – pleurodesis in rabbits without provoking inflammation in the pleural space [29–31]. However (according to our knowledge), this agent has not yet been authorized for pleurodesis in humans.

Table 1. Outcome of pleurodesis in patients with pleural metastatic tumors of different origins after talc pleurodesis (source: our personal series)

<table>
<thead>
<tr>
<th>Tumor origin</th>
<th>Complete success n</th>
<th>Partial success n</th>
<th>Failure of pleurodesis n</th>
<th>Median survival after pleurodesis months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung (n = 109)</td>
<td>72 (66%)</td>
<td>21 (19%)</td>
<td>16 (15%)</td>
<td>4.4 (0.3–44)</td>
</tr>
<tr>
<td>Breast (n = 95)</td>
<td>74 (78%)</td>
<td>12 (13%)</td>
<td>9 (9%)</td>
<td>8.8 (0.2–153)</td>
</tr>
<tr>
<td>Mesothelioma (n = 69)</td>
<td>41 (59%)</td>
<td>11 (16%)</td>
<td>17 (25%)</td>
<td>9.6 (0.5–58)</td>
</tr>
<tr>
<td>Lymphoma (n = 34)</td>
<td>25 (73%)</td>
<td>6 (18%)</td>
<td>3 (9%)</td>
<td>11.8 (0.3–137)</td>
</tr>
<tr>
<td>Ovary (n = 26)</td>
<td>20 (77%)</td>
<td>3 (11.5%)</td>
<td>3 (11.5%)</td>
<td>6.3 (0.1–92)</td>
</tr>
<tr>
<td>Colon (n = 19)</td>
<td>16 (85%)</td>
<td>1 (5%)</td>
<td>2 (10%)</td>
<td>8.1 (0.3–86)</td>
</tr>
<tr>
<td>Kidney (n = 18)</td>
<td>12 (67%)</td>
<td>4 (22%)</td>
<td>2 (11%)</td>
<td>3.4 (0.1–12)</td>
</tr>
<tr>
<td>Stomach (n = 13)</td>
<td>9 (69%)</td>
<td>2 (15.5%)</td>
<td>2 (15.5%)</td>
<td>2.1 (0.6–10)</td>
</tr>
<tr>
<td>Other origin (n = 21)</td>
<td>18 (86%)</td>
<td>2 (9.5%)</td>
<td>1 (4.5%)</td>
<td>3.5 (0.6–98)</td>
</tr>
<tr>
<td>Sarcoma (n = 7)</td>
<td>4 (57%)</td>
<td>3 (43%)</td>
<td>0</td>
<td>2.1 (0.8–10)</td>
</tr>
<tr>
<td>Unknown origin (n = 49)</td>
<td>35 (71%)</td>
<td>11 (22%)</td>
<td>3 (7%)</td>
<td>4.1 (0.2–30)</td>
</tr>
<tr>
<td>Total (n = 460)</td>
<td>326 (70.9%)</td>
<td>76 (16.5%)</td>
<td>58 (12.6%)</td>
<td></td>
</tr>
</tbody>
</table>

Outcome of Pleurodesis in Different Types of Tumors in the Pleura

The role of the tumor type spreading to the pleural surfaces might determine the response to pleurodesis [32, 33]. In a combined two-center study evaluating the outcome of thoracoscopic talc poudrage and bedside doxycycline pleurodesis in different tumor types, we found that the type of tumor involving the pleural surfaces influences significantly the success of pleurodesis, regardless of the sclerosing agent used. Malignant effusion due to mesothelioma and lung cancer are particularly prone to induce the failure of pleurodesis, while outcome seems better in patients with breast or ovarian cancer. Similar good results were obtained with pleurodesis in lymphoma patients according to our talc pleurodesis series (table 1). A potential explanation could be that a trapped lung is relatively common in mesothelioma and metastatic tumors of the lung as a result of either visceral pleural restriction (mesothelioma) or endobronchial obstruction (lung cancer). Also, we found that a high tumor burden in the pleural space was negatively associated with the results of pleurodesis [34]. This indicates that the likelihood of achieving a successful pleurodesis decreases with an increasing pleural tumor burden observed during thoracoscopy. However, according to logistic regression analysis, tumor burden by itself did not account for the varying success rates of talc poudrage among the tumor groups in our study. Besides the above-mentioned mechanical explanation, other biological mechanisms may also be involved in the failure of pleurodesis (especially in mesothelioma), probably because the high tumor burden is jeopardizing the role that normal mesothelial cells would play in achieving a good pleural symphysis.

The Choice of Sclerosants for Pleurodesis

According to a Cochrane database [35] and another systematic review [36], talc is considered the best sclerosant for pleurodesis regarding the rate of success. In a randomized multicenter study, Dresler et al. [37] observed about the same overall efficacy for talc in ‘poudrage’ and ‘slurry’ forms, but they found that poudrage was better in pleural metastatic lung and breast carcinomas. In another randomized study comparing talc pou-
drage and slurry, Mañes et al. [38] observed a higher rate of recurrences with talc in ‘slurry’ form than with pou-
drage. Other potential disadvantages of slurry include lack of uniform distribution and accumulation in adja-
cent areas of the pleural cavity, with subsequent incom-
plete pleurodesis and multiloculations. Also, we have ob-
served that most of the talc administered in slurry form
might be eventually eliminated through the chest tube
after unclamping the drain [39].

In addition to inducing the best results in pleurodesis,
recent studies seem to show a local antitumor effect of
talc by triggering apoptosis in cancer cells [40] and by al-
tering the angiostatic balance via endostatin [41]. Defec-
tive apoptotic signalling pathways have an important role
in the initiation and progression of cancer, and they are
related with tumor aggressiveness and short survival. If
the above results are confirmed in larger series, talc would
play a significant role in controlling not only pleural ef-
fusion but also intrapleural tumor progression.

Other agents that are gaining acceptance for pleurode-
sis are iodopovidone [42, 43] and silver nitrate [44]. Instil-
lation of doxycycline through a small-bore catheter is
also a good choice for bedside pleurodesis [45], although
intrapleural injection of lidocaine prior to the procedure
and premedication to alleviate anxiety and pain are man-
datory in this case.

Mechanisms Associated with Complications of
Pleurodesis

Thoracoscopy is associated with a transient impair-
ment in lung function, which is more pronounced when
pleurodesis is performed [46]. With the exception of some
complications related to the technique itself [47], which
could be prevented using ultrasound examination, the
most relevant are systemic complications associated with
intrapleural instillation of the sclerosant.

Acute Respiratory Distress or Pneumonitis

This has been described in some cases of talc pleurode-
sis [48, 49], but the pathophysiologic mechanism respon-
sible for this severe complication is still unclear. A cause
of concern is systemic inflammation, which apparently
commonly occurs following instillation of almost all
agents into the pleural space [50] and administration of
talc-containing small particles (<10 mm in diameter)
[51]. A large European multicenter study on the safety of
talc poudrage including 558 patients with MPE treated
with 4 g of large-particle talc (median diameter: 25.6 mm)
found no cases of acute respiratory distress [52]. On the
contrary, in a recent study from a North American center,
talc-related lung injury was noted in 4 of 143 procedures
(2.8%), and talc exposure might have contributed to the
respiratory deterioration in 4 additional patients [53].
The talc used for this study (the only one approved by the
US Food and Drug Administration for intrapleural in-
stillation) had a smaller particle size than the one most
frequently used in Europe [54]. Acute respiratory compi-
lcations arise more frequently in patients with poor clinical
condition at the time of pleurodesis, and careful eval-
uation of the performance status of those patients prior
to thoracoscopy and pleurodesis is therefore highly rec-
commended.

Possible Activation of Systemic Coagulation after
Pleurodesis

There is evidence that thoracoscopy – like many other
interventional procedures – can provoke systemic in-
flammation, but it is clear that talc pleurodesis induces a
stronger reaction in many cases [55, 56]. In an experi-
mental study on talc slurry treatment in rabbits, promi-
nent perivascular infiltrates were found in the underlying
lung, and the authors speculated that some mediators
might spread from the pleura to the pulmonary circula-
tion [57].

As quoted elsewhere in this article, coagulation was
increased and fibrinolytic activity was decreased in the
pleural space after intrapleural application of talc. If sys-
temic inflammation is concurrently present, the possible
systemic implications of the pleural coagulation-fibrino-
lysis imbalance involved in the pleurodesis process itself
might be the cause of concern. Prompted by this concern
and by several cases of massive pulmonary embolism af-
after talc pleurodesis, we concomitantly determined pleu-
ral/plasma markers of coagulation and fibrinolysis and
found that activation of systemic coagulation is frequent-
ly observed after talc poudrage [58], and that this side ef-
fect can be partially controlled with prophylactic heparin
[59].

We have recently reported that IL-8, which is increased
in the pleural fluid after talc treatment, activates the
cogulation cascade and correlates with survival after talc
pleurodesis [60]. The relevance of this finding in clinical
practice is still unclear, but some premature deaths fol-
lowing pleurodesis may be in part related to undetected
thrombosis and/or pulmonary embolism, and not only to
advanced neoplastic disease, as it is commonly believed.
This concern applies not only to talc, but also to other
c sclerosants [Rodriguez-Panadero, unpubl. results], and

Rodriguez-Panadero/Montes-Worboys
we therefore advise – despite some possible impairment in the mechanisms leading to pleurodesis [61] – giving subcutaneous prophylactic heparin to patients who are submitted to pleurodesis during the whole hospitalization period.

Conclusion

In summary, the pleural mesothelial cell is the primary target for the sclerosant and plays a pivotal role in the whole pleurodesis process, including diffuse inflammation, pleural coagulation-fibrinolysis imbalance (favoring the formation of fibrin adhesions), fibroblast recruitment, and subsequent proliferation and production of collagen after intrapleural application of the sclerosing agent. When the tumor burden is high, normal mesothelial cells are scarcely present, and then the response to the sclerosing agent is lower, leading to failure of pleurodesis. Complications associated with pleurodesis might be minimized using large-particle talc and prophylactic treatment with subcutaneous heparin during hospitalization. However, it should be borne in mind that heparin prophylaxis could interfere – to some degree – with the mechanisms leading to a successful pleurodesis, and the pros and cons have to be balanced in clinical decision making.

Acknowledgments

We thank Dr. Lourdes Gomez-Izquierdo for figures 1 and 2. Part of the work quoted in this article was supported by grants (FIS 98/0419, FIS 01/0595 and FIS 04/0289 from the Instituto de Salud Carlos III, Spain).

References

5. Hartman DL, Antony VB, Hott JW, Godbey SW, Yu L, Rodríguez Panadero F: Thoraco-
6. Xie C, Teixeira LR, McGovern JP, Light RW: Systemic corticosteroids decrease the effec-
8. Agrenius V, Chmielewska J, Widström O, Blömback M: Increased coagulation activity of the pleura after tube drainage and quin-
acrine instillation in malignant pleural effu-
9. Agrenius V, Chmielewska J, Widström O, Blömback M: Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of ma-
12. Montes JF, García-Valero J, Ferrer J: Evi-
15. Rodríguez Panadero F, Gómez Izquierdo L, Martin Juan J, Borderas F, Sánchez JF, Segu-
ragui DI: The balance between expression of plasminogen activators and their inhibitor (PAI-1) in pleural tissue is associated to out-
come of talc pleurodesis. Am J Respir Crit Care Med 1997;155:739.
16. Pinkas K, Calderon-Osuna E, Romero-Romero B, Martín Juan J, Navarro C, Sánchez JF, Sé-
gura DI: C-C (monocyte chemo-
attractant peptide) and C-X-C (interleukin 8) chemo-


52 Neto JD, de Oliveira SF, Vianna SP, Terra RM: Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respiriology 2010;15:115–118.


Erratum

In the article by Rodriguez-Panadero and Montes-Worboys, entitled ‘Mechanisms of Pleurodesis’ [Respiration 2012;83:91–98], millimeters (mm) were used instead of micrometers (μm). The correct text on page 96, left column, last paragraph should read as follows:

Acute Respiratory Distress or Pneumonitis

This has been described in some cases of talc pleurodesis [48, 49], but the pathophysiologic mechanism responsible for this severe complication is still unclear. A cause of concern is systemic inflammation, which apparently commonly occurs following instillation of almost all agents into the pleural space [50] and administration of talc-containing small particles (<10 μm in diameter) [51]. A large European multicenter study on the safety of talc poudrage including 558 patients with MPE treated with 4 g of large-particle talc (median diameter: 25.6 μm) found no cases of acute respiratory distress [52].